Mount Sinai Begins Pilot of Respiratory Disease Management Platform
November 13, 2014 – The Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai is conducting an investigational pilot study of a respiratory disease management platform, developed by Cohero Health, in pediatric asthma patients seen …
Research Funding & Sponsorship Opportunity: Novo Nordisk Diabetes and Obesity Biologics Science Forum
Novo Nordisk is inviting a limited number of leading US academic and medical research institutions to announce this opportunity among those faculty members who could potentially have novel ideas for biologics innovation within diabetes and obesity research. These Awards can be granted …
Mount Sinai Innovation Partners: Open Positions
Mount Sinai Innovation Partners, MSIP, is actively searching for qualified candidates for a number of open positions. To learn more about the opportunities and becoming a part of the Mount Sinai community, click on the links below. Business Development Director Business Development …
Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C
July 22, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (otcqb:NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use …
Future of health: LifeMap grabs $5M, partners with Mount Sinai School of Medicine on big data-powered mobile health platform
For better or for worse, we’re living in an era of near constant self-quantification. From wi-fi enabled bathroom scales, to activity monitoring wristbands, to personal DNA sequencing, consumers are gathering more data about their health and wellness than at any time in …
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
SPRING HOUSE, Pa., May 5, 2014 /PRNewswire/ — Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire …
Auven Therapeutics and BELLUS Health Announce License Agreement with Mount Sinai for KIACTA in Sarcoidosis
May 2, 2014 – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that Auven has entered into a license …
Technology Transfer: Commercialization and Innovation Infographic
by AvalancheInfographics. Explore more visuals like this one on the web’s largest information design community – Visually. …
Intranasal Ketamine Confers Rapid Antidepressant Effect in Depression
April 8, 2014 – A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major …
Harrington Scholar-Innovator Grant Program
The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between …